
14.2.2 Secondary endpoints

14.2.2.10 Incidence of non-relapse mortality

Figure 14.2.2.10.1: Cumulative incidence of NRM and relapse from eligibility - Full Analysis Population



ContRuxo: Ruxolitinib continuous therapy. SCT: Allogeneic stem cell transplantation.

Table 14.2.2.10.1: Cumulative incidence of NRM and relapse at 100 days, 1 year, 2 years and 3 years after start of investigational treatment - Full Analysis Population

Timepoint	Event	Treatment arm	Cumulative incidence Function Estimate	Standard Error	95% Lower confidence interval	95% Upper confidence interval
100 days	NRM (Non-relapse mortality)	ContRuxo	0.000	0.000	-	-
		SCT	0.000	0.000	-	-
	Relapse	ContRuxo	0.214	0.114	0.048	0.458
		SCT	0.018	0.018	0.001	0.083
1 years	NRM (Non-relapse mortality)	ContRuxo	0.000	0.000	-	-
		SCT	0.055	0.031	0.014	0.138
	Relapse	ContRuxo	0.476	0.153	0.177	0.728
		SCT	0.107	0.042	0.043	0.205

ContRuxo: Ruxolitinib continuous therapy. NRM: Non-relapse mortality (death before any relapse). SCT: Allogeneic stem cell transplantation.
Specified timepoints are defined as timepoint + 92 days after the date of inclusion to allow for Ruxolitinib induction period. All numerical values are rounded to 3 decimal places.

Page 1 of 2